Psoriasis

Test your knowledge of psoriasis treatment options with our 5-question quiz.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in psoriasis this year.

Most studies involving the treatment of psoriasis do not contain any images of patients, a review finds.

Experts in dermatology delve into patient communication regarding treatment expectations, emphasizing the significance of ongoing follow-up and maintenance practices. They also address the safety, tolerability, and comfortability aspects associated with the use of this novel TYK-2 inhibitor, drawing insights from long-term clinical trial data.

Linda Stein-Gold, MD, Mona Shahriari, MD, and Micheal Cameron, MD, FAAD explore emerging oral treatments for the management of plaque psoriasis, emphasizing the novelty of TYK-2 inhibition. They discuss the unique POETYK trial design, stressing the importance of the inclusion of an active control arm. Lastly, they highlight the clinical efficacy of this novel treatment MOA.

Read the top 10 takeaways from a recent discussion among experts in the management of plaque psoriasis.

Lisa Swanson, MD, FAAD, and Robert Casquejo, PA-C, discuss their preferred treatment approach for plaque psoriasis, which includes PDE4 inhibitors such as apremilast and roflumilast.

Experts in dermatology share insights on considering the location's impact in treating plaque psoriasis, focusing on challenges with scalp involvement and addressing limitations with topical therapies.

Lisa Swanson, MD, FAAD and Robert J. Casquejo, PA-C highlight the impact of plaque psoriasis on both moderate and mild patients, emphasizing the importance of addressing these concerns in patient care.

52% of adult patients achieved the treat-to-target goal of 1% BSA or less within 3 months of incorporating tapinarof cream into their biologic regimen.

Study authors hypothesize that a monoclonal blockade of pathogenic T cells may induce expansion of regulatory immune cells subsets or expression of cytokines involved in skin homeostasis.

Investigators explored the genetic relationship between psoriatic disease and serum lipid levels.

Approximately 96.2% of patients had achieved PASI75 by week 12 of the study.

Researchers explored the potential causal relationship between pure hypercholesterolemia, a recognized risk factor for cardiovascular disease, and psoriasis.

The US license period will start on February 22, 2025.

Depression, functional impairment, and worsened quality of life are related in patients with psoriatic disease, according to a recent study.

Because of the chronic inflammatory state of psoriasis and the immunosuppression produced by some systemic medications, patients with psoriasis may have an increased risk of lymphoma and nonmelanoma skin cancer.

Label warnings may affect the initiation of new treatment and real-world switching patterns for psoriasis patients starting treatment with risankizumab.

Bimekizumab is the first dual IL-17 A/F inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7,200 per syringe.

In addition to improvements in work productivity, tildrakizumab also demonstrated significant efficacy and safety.

Investigators noted that patients with mild psoriasis experience a less favorable status when compared to patients with moderate psoriasis.

PASI scores were significantly correlated with sleep quality, duration, and disturbances.

Authors of the case report that little is known about the associations between psoriasis and renal function.

The approved indication makes Wezlana the first approved interchangeable biosimilar to Stelara.

Leah Howard, JD, of the National Psoriasis Foundation, discusses the importance of advocacy in psoriasis, the role of mental health in chronic skin conditions, and the role of support organizations in advocating for awareness and health equity.